GlassScriptPhysician profile
James K Schwarz
NPI 1710968847
$2,718.11
in general payments reported to CMS, 2019-2025
49 companies · $42.38 in 2025
The $42.38 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.22 · 2021: $700 · 2022: $764 · 2023: $839 · 2024: $342 · 2025: $42.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $344.71 | 2021-2023 | Opdivo, Opdualag |
| Seagen INC. | $170.21 | 2021-2023 | Tukysa, Padcev |
| Pfizer INC. | $169.55 | 2020-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $112.86 | 2021-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $109.55 | 2022-2024 | |
| Genentech USA, INC. | $107.08 | 2021-2024 | Tecentriq |
| Genzyme Corporation | $88.84 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $87.97 | 2021-2024 | Keytruda |
| Octapharma USA, INC. | $80.71 | 2022-2025 | Octagam Immune Globulin (Human) |
| Eisai INC. | $72.58 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $68.41 | 2022-2023 | |
| Glaxosmithkline, LLC. | $67.95 | 2021-2022 | |
| Blueprint Medicines Corporation | $60.86 | 2020-2023 | Ayvakit |
| Incyte Corporation | $59.72 | 2021-2023 | Pemazyre, Monjuvi |
| Lilly USA, LLC | $54.33 | 2021-2024 | Verzenio, Jaypirca |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schwarz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.